Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

An expected delay in a key step in CK Hutchison's planned sale of its Panama ports to a U.S. group, a deal blasted by Chinese ...

After revolutionizing the weight-loss drug market, Novo Nordisk (NVO) and Eli Lilly (LLY) are setting their sights on heart ...

Compounded versions could make up as much as 40% of the semaglutide market, said Novo Nordisk CEO Lars Fruergaard Jorgensen ...

Obesity drug giant Novo Nordisk said Thursday that the rampant growth of the U.S.'s compounded drug industry was hurting ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

The Woodlands, Texas-based Lexicon has been studying LX9851 as a standalone therapy and in combination with GLP-1 agonists such as semaglutide, the main ingredient in Novo Nordisk’s Wegovy.

Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...